Hemodynamic effects of vasodilator therapy (phentolamine or nitroprusside) were studied in 38 patients with acute myocardial infarction (AMI 
D ESPITE A BETTER UNDERSTANDING of the physiology of acute myocardial infarction, the prognosis of overt pump failure or cardiogenic shock following infarction remains poor with conventional therapy. Traditionally "pump failure" with reduced cardiac output and pulmonary venous congestion has been treated with diuretic and inotropic agents. Although diuretics may reduce the symptoms of pulmonary venous congestion, they do CHATTERJEE ET AL.
like digitalis or norepinephrine, have variable hemodynamic effects in patients with recent myocardial infarction.2 3 Furthermore, the more severe the pump failure, the less effective are these therapeutic agents. 4 Recent experimental and clinical investigations suggest that inotropic agents may also enhance ischemia and the magnitude of muscle destruction in the presence of recent infarction. 5 Recently, vasodilator drugs like phentolamine and nitroprusside, agents capable of reducing peripheral resistance, have been shown to improve cardiac performance in chronic congestive heart failure as well as in patients with acute infarction."-9 However, the patients with acute infarction who are likely to benefit from such therapy have not been clearly defined. Furthermore, no information is yet available about the metabolic effects of these agents in patients with acute myocardial infarction.
The purpose of this study, therefore, was to evaluate hemodynamic and metabolic responses to vasodilator therapy in patients with acute myocardial infarction. Results suggest that significant improvement in cardiac performance occurs during vasodilator therapy even in the presence of severe pump failure. In order to clarify whether improved cardiac performance was due to direct inotropic effects of sodium nitroprusside and phentolamine, in vitro effects of these agents on isolated cat papillary muscles were also studied.
Methods Patient Population
Hemodynamic responses to vasodilator therapy were studied in 38 patients (eight females, 30 males, ages 35-78) with historical, ECG, and laboratory evidence of myocardial infarction. Six patients (nos. 3, 4, Thirty-six patients were investigated within 72 hours of the onset of infarction. One patient was studied on the eighth day and another at six weeks following infarction for persistent congestive failure. Twenty patients had anterior, eight inferior, six both anterior and inferior and three subendocardial infarction. In one patient who developed left bundle branch block acutely, the site of infarct could not be determined. Nine patients were in clinical shock at the time of study. Shock was diagnosed when features of diminished organ perfusion (cold, clammy skin, mental obtundation, and oliguria) and hypotension (systolic blood pressure by cuff, 90 mm Hg or less) were present. Twenty-three patients had frank pulmonary edema and seven, mild to moderate pulmonary congestion at the time of the study. The remaining eight patients did not have any clinical evidence of pulmonary venous congestion.
Vasodilator Therapy Phentolamine was used intravenously by a constant infusion pump (Harvard) in 11 patients. Five mg of phentolamine were administered in the first minute and then at a rate of 0.1 to 2 mg/min. Nitroprusside was infused in the remaining 27 patients at a rate of 16 to 200 ,ug/min with the use of an infusion flow controller.* The infusion rate of phentolamine or nitroprusside was gradually increased until the mean arterial pressure decreased by not more than 20 mm Hg or when there was a significant decrease in the pulmonary capillary wedge pressure. The infusion rate of nitroprusside was then kept constant and hemodynamic and metabolic measurements were repeated.
Hemodynamic and Metabolic Measurements
Arterial pressure (AP) was monitored continuously through a 20 gauge cannula inserted into the radial artery. Right atrial (RA), pulmonary artery (PA), and pulmonary capillary wedge (PCW) pressures were recorded through a balloon-tip triple lumen catheter. Cardiac output (CO) was measured by thermodilution techniques with the same catheter. 10 11, 12 Coronary sinus flow (CSF) was measured by the constant infusion thermodilution technique.12' 13 For this purpose a special preshaped catheter was inserted into the coronary sinus.13 Blood samples from the coronary sinus and radial artery were analyzed for pH, pC02, and pO.. by a pH/gas analyzer, model 113*.
Hemoglobin saturation was determined with a COoximeter model 182.* Samples of arterial and coronary sinus blood were also taken for determination of lactate concentration by an automated modification of the enzymatic method of Hohorst. 14 Derived hemodynamic and metabolic parameters were calculated as follows:
Stroke volume index (SVI) = SV/body surface area (BSA) (m1/M2) therefore, the results for both drugs have been grouped together. The effects of each drug were fully manifest 5 min after reaching the desired infusion rate. The steady state hemodynamic changes observed during vasodilator therapy in all three groups are detailed in tables 2-4. The usual hemodynamic response in each group was decreased systemic and pulmonary vascular resistance; decreased pulmonary artery, right atrial and left ventricular filling pressures; together with a slight to moderate decrease in mean arterial pressure.
However, in three patients in group I, three in group II, and five in group III, there was no significant change in AP. During vasodilator therapy in these patients, AP was unchanged, while PCW pressure was reduced and CI usually increased. There was no significant change in heart rate in group II and III patients although it usually increased in group I patients. Cardiac index increased consistently in group II and III patients, but not in group I patients. Hemodynamic responses were similar in both previously hypertensive and normotensive patients. response to phentolamine infusion, the LVFP decreased from 22 to 8 mm Hg, and SVI increased from 26 to 34 ml/m2, together with a fall in systemic vascular resistance; with a further increase in the infusion rate, there was a further reduction in LVFP to 5 mm Hg and SVI decreased to 26 ml/m2. It appears, therefore, that improved cardiac performance may not occur in patients with a normal LVFP, but significant improvement may be expected in patients with an elevated LVFP and depressed cardiac performance. Due to a reduction in arterial pressure of variable magnitude, changes in derived SWI were also variable ( fig. 3) 
